DE10148436A1 - Tetrahydrochinoline - Google Patents

Tetrahydrochinoline

Info

Publication number
DE10148436A1
DE10148436A1 DE10148436A DE10148436A DE10148436A1 DE 10148436 A1 DE10148436 A1 DE 10148436A1 DE 10148436 A DE10148436 A DE 10148436A DE 10148436 A DE10148436 A DE 10148436A DE 10148436 A1 DE10148436 A1 DE 10148436A1
Authority
DE
Germany
Prior art keywords
compounds
mmol
formula
spirocyclobutyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10148436A
Other languages
German (de)
English (en)
Inventor
Heike Gielen
Siegfried Goldmann
Joerg Keldenich
Holger Paulsen
Carsten Schmeck
Stephan Siegel
Hilmar Bischoff
Martin Raabe
Delf Schmidt
Christiane Faeste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE10148436A priority Critical patent/DE10148436A1/de
Priority to DO2002000457A priority patent/DOP2002000457A/es
Priority to JP2003532059A priority patent/JP2005508341A/ja
Priority to PCT/EP2002/010444 priority patent/WO2003028727A1/de
Priority to EP02772317A priority patent/EP1434581A1/de
Priority to US10/491,465 priority patent/US20050043341A1/en
Priority to CA002462030A priority patent/CA2462030A1/en
Priority to ARP020103608A priority patent/AR036583A1/es
Priority to UY27458A priority patent/UY27458A1/es
Priority to GT200200195A priority patent/GT200200195A/es
Priority to PE2002000962A priority patent/PE20030604A1/es
Priority to HN2002000278A priority patent/HN2002000278A/es
Publication of DE10148436A1 publication Critical patent/DE10148436A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10148436A 2001-10-01 2001-10-01 Tetrahydrochinoline Withdrawn DE10148436A1 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE10148436A DE10148436A1 (de) 2001-10-01 2001-10-01 Tetrahydrochinoline
DO2002000457A DOP2002000457A (es) 2001-10-01 2002-09-02 Tetrahidroquinolinas
JP2003532059A JP2005508341A (ja) 2001-10-01 2002-09-18 ３−ヒドロキシ−（４−トリフルオロメチルフェニル）−メチル−７−スピロシクロブチル−５，６，７，８−テトラヒドロキノリン−５−オール誘導体およびコレステロールエステル転送タンパク質（ｃｅｔｐ）阻害剤としてのその使用
PCT/EP2002/010444 WO2003028727A1 (de) 2001-10-01 2002-09-18 3-`hydroxy- (-4-trifluoromethylphenyl) -methyl!-7-spirocyclobutyl-5,6,7,8- tetrahydrochinolin-5-ol-derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren
EP02772317A EP1434581A1 (de) 2001-10-01 2002-09-18 3-[hydroxy-(4-trifluoromethylphenyl)-methyl]-7-spirocyclobutyl-5,6,7,8-tetrahydrochinolin-5-ol- derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren
US10/491,465 US20050043341A1 (en) 2001-10-01 2002-09-18 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
CA002462030A CA2462030A1 (en) 2001-10-01 2002-09-18 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
ARP020103608A AR036583A1 (es) 2001-10-01 2002-09-25 Compuestos de tetrahidroquinolinas, un procedimiento para su preparacion, medicamentos y el uso de dichos compuestos para la preparacion de medicamentos
UY27458A UY27458A1 (es) 2001-10-01 2002-09-27 Tetrahidroquinolinas
GT200200195A GT200200195A (es) 2001-10-01 2002-09-27 Tetrahidroquinolinas
PE2002000962A PE20030604A1 (es) 2001-10-01 2002-09-30 Tetrahidroquinolinas
HN2002000278A HN2002000278A (es) 2001-10-01 2002-10-01 Tetrahidroquinolinas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10148436A DE10148436A1 (de) 2001-10-01 2001-10-01 Tetrahydrochinoline

Publications (1)

Publication Number Publication Date
DE10148436A1 true DE10148436A1 (de) 2003-04-17

Family

ID=7701007

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10148436A Withdrawn DE10148436A1 (de) 2001-10-01 2001-10-01 Tetrahydrochinoline

Country Status (12)

Country Link
US (1) US20050043341A1 (enExample)
EP (1) EP1434581A1 (enExample)
JP (1) JP2005508341A (enExample)
AR (1) AR036583A1 (enExample)
CA (1) CA2462030A1 (enExample)
DE (1) DE10148436A1 (enExample)
DO (1) DOP2002000457A (enExample)
GT (1) GT200200195A (enExample)
HN (1) HN2002000278A (enExample)
PE (1) PE20030604A1 (enExample)
UY (1) UY27458A1 (enExample)
WO (1) WO2003028727A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319509A1 (en) 2003-09-26 2011-05-11 Japan Tobacco, Inc. Method of Inhibiting remnant lipoprotein production
ES2332051T3 (es) 2003-10-08 2010-01-25 Eli Lilly And Company Compuestos y procedimientos para tratar dislipidemia.
AU2005230915A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006063828A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
US20080145498A1 (en) * 2006-12-14 2008-06-19 Kraft Foods Holdings, Inc. Texture and shape control process for acidified food products
ATE520696T1 (de) * 2008-03-05 2011-09-15 Boehringer Ingelheim Int Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016037534A1 (en) * 2014-09-09 2016-03-17 Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. Novel process for preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline

Also Published As

Publication number Publication date
CA2462030A1 (en) 2003-04-10
JP2005508341A (ja) 2005-03-31
AR036583A1 (es) 2004-09-15
EP1434581A1 (de) 2004-07-07
WO2003028727A1 (de) 2003-04-10
PE20030604A1 (es) 2003-09-07
US20050043341A1 (en) 2005-02-24
UY27458A1 (es) 2003-04-30
GT200200195A (es) 2003-08-22
WO2003028727A9 (de) 2003-11-13
DOP2002000457A (es) 2003-04-15
HN2002000278A (es) 2002-12-20

Similar Documents

Publication Publication Date Title
EP0818448B1 (de) Cycloalkano-pyridine als CETP-Inhibitoren
EP0818197B1 (de) Heterocyclisch kondensierte Pyridine als CETP Inhibitoren
EP0796846B1 (de) 2-Aryl-substituierte Pyridine
EP1017659B1 (de) Substituierte tetrahydro-naphtaline und analoge verbindungen
EP1017692B1 (de) 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep)
EP1017677A1 (de) 4-phenyltetrahydrochinoline als hemmer des cholesterolestertransferproteins
EP0970053A1 (de) 5-oxysubstituierte chinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep)
EP0825185A1 (de) Bicyclisch kondensierte Pyridine
DE10148436A1 (de) Tetrahydrochinoline
WO2006072362A1 (de) (5s) - 3 - [(s)-fluor (4-trifluoromethylphenyl) methyl] -5,6,7,8-tetrahydrochinolin-5-ol derivative und ihre verwendung als cetp-inhibitoren
EP1017658A1 (de) Benzyl-biphenyle und analoge verbindungen und deren verwendung zur behandlung von arteriosklerose und diylipidämien
DE19704244A1 (de) 5-Hydroxy-alkyl substituierte Phenyle
EP0973744A1 (de) 2-amino-substituierte pyridine verwendbar zur behandlung von arteriosklerose und hyperlipoproteinemie
EP1828137B1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE19832159A1 (de) Substituierte Tetrahydro-naphthaline
DE102004060997A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061001A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061002A1 (de) Chemische Verbindung und ihre Verwendung
DE102004060998A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061003A1 (de) Chemische Verbindung und ihre Verwendung
DE102004060999A1 (de) Chemische Verbindung und ihre Verwendung
DE102004061000A1 (de) Chemische Verbindung und ihre Verwendung

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: BAYER HEALTHCARE AG, 51373 LEVERKUSEN, DE

8139 Disposal/non-payment of the annual fee